Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

Exclusion Criteria

• •Participant has multiorgan transplants (with the exception of pancreas and corneal transplants).
• •Immunosuppressive therapy (IST) regimen for kidney transplant or other systemic chronic ISTs including enteric budesonide that is not stable for \>6 weeks prior to Day 1. Exceptions include routine changes in the dose of CNIs to meet target level.
• •\<3 months after antirejection treatment and active rejection.
• •Active bacterial, fungal or viral infection and/or active treatment of infection including BK virus (BKV), cytomegalovirus (CMV), human immunodeficiency virus (HIV), Hepatitis B and C \<3 months prior to and during the screening period.
• •Current treatment for surgical complications.
• •History of heart failure (New York Heart Association \[NYHA\] Class II-IV).
• •Jaundice, hepatitis, or known hepatobiliary disease.
• •Malignancy within the past 2 years with the exception of adequately treated basal cell carcinoma or non-metastatic squamous cell carcinoma of the skin, with no evidence or recurrence.
• •History of alcohol or illicit drug use disorder (as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition).
• •History of serious side effects or allergic response to any angiotensin II antagonist or ERA.
• •Participant requires any of the prohibited concomitant medications.
• •Treatment with sparsentan \<12 weeks prior to screening.
• •Participant has participated in a study of another investigational product \<28 days prior to screening or plans to participate in such a study during the course of this study.
• •Hematocrit \<27%, hemoglobin \<90 g/L (9 g/dL), or potassium \>5.5 mmol/L (5.5 mEq/L).
• •The participant is pregnant, plans to become pregnant during the course of the study, or is breastfeeding.
• •The participant, in the opinion of the Investigator, is unable to adhere to the requirements of the study, including the ability to swallow the study IMP whole.
• •The participant, in the opinion of the Investigator, has a medical condition or abnormal clinically significant laboratory screening value not listed above that may interfere with the evaluation of sparsentan safety or activity.